| |
Combining the industry-leading GPEx®️ cell line development with streamlined drug substance manufacturing. 
|
|
Today’s Big NewsDec 16, 2024 |
|
Just secured round from NVIDIA & Accel, Nebius is revolutionizing Life Sciences and Healthcare with powerful GPU Cloud. Cutting-edge AI/ML solutions, competitive pricing, and expert architectural support for breakthrough research. Learn more. 
|
|
| By Gabrielle Masson Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies said. |
|
|
|
By James Waldron Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug came up short in a phase 1 study in patients with acute myeloid leukemia. |
By James Waldron Fierce Biotech recounts the biggest biotech blunders and one inspiring intervention in the 2024 edition of Rotten Tomatoes. |
Sponsored by Inventus Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are contributing to better patient outcomes with the only seamless global connectivity solution for eCOA. |
By James Waldron Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker believes has blockbuster potential with a mitochondrial disease. |
By James Waldron Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to launch a phase 2 trial of trial of its Duchenne muscular dystrophy therapy on hold. |
By James Waldron Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a phase 2 trial. |
By James Waldron PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis. |
By James Waldron In the wake of the approval Bristol Myers Squibb’s Cobenfy, it seems that news has ramped up in the schizophrenia space. The latest contender is Reviva Pharmaceuticals’ brilaroxazine, which reduced schizophrenia symptoms over a year in a phase 3 trial. |
By Darren Incorvaia After its eye disease drug flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is laying off 23% of staff. |
By Darren Incorvaia Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed to improve symptoms in a phase 1/2 trial. |
By Angus Liu Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. |
By Paige Minemyer In the days that followed the murder of UnitedHealthcare CEO Brian Thompson last week, many across the internet have unleashed their frustration and anger with a healthcare system that leaves people behind far too often. |
By Fraiser Kansteiner Novo Nordisk is laying out 8.5 billion Danish kroner (about $1.2 billion) to establish a new manufacturing plant in Odense, Denmark, where the company eventually plans to hire on 400 permanent staffers. The modular factory will be kitted out to produce multiple drugs within rare disease indications, including hemophilia. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we hear from Novo Nordisk CSO Marcus Schindler about his role at the Danish pharma and what’s next for the GLP-1 drug class. |
|
|---|
|
|
|
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
